Jim Cramer Doesn't Like This Health Care Stock, Sees No Reason To Buy Rambus

Jim Cramer was negative on Rambus and MiniMed, called GigaCloud highly speculative, and described Babcock & Wilcox as a speculation while advising investors not to commit too much. He was positive on Archer-Daniels-Midland and Deere; ADM is scheduled to report Q3 results on Nov. 3, with analysts expecting EPS of $1.57 and revenue of $22.98 billion. Wednesday share moves were mixed: Accelevation fell 7.4%, Babcock & Wilcox 4.6%, and Rambus 2.3%, while GigaCloud rose 2.2%.

Analysis

This is primarily an attention-and-positioning story, not new evidence about earnings power. Cramer’s comments may create short-lived retail flows, but they are weak standalone signals; the scheduled earnings events matter more if they change guidance or cash-flow expectations.

Near term, treat Rambus’s upcoming results as the actual catalyst: a negative TV soundbite is not a thesis to short, and the key verification is whether management provides a credible growth driver or outlook change. For MiniMed, the first coverage target is an anchor, not validation; the gap between that target and the cited share price does not establish value without reviewing the standalone company’s growth, margins, and post-separation capital structure.

Babcock & Wilcox’s limited notice to proceed provides project optionality, but the economic value depends on conversion to full scope, funding, and execution. Do not capitalize the announced project amount as assured revenue or cash flow. GigaCloud’s prior beat likewise needs confirmation in subsequent guidance and cash conversion before it offsets its speculative profile. Accelevation’s IPO weakness is a supply/price-discovery warning, not enough evidence to infer fundamental impairment.

ADM has the clearest near-term event, but an earnings trade should hinge on processing economics, volumes, and guidance—not an endorsement or an agriculture-election narrative. Deere may benefit from stronger farm-capex expectations, but its demand cycle need not track ADM’s commodity-processing drivers. Over 6–18 months, sustained operating evidence could support fundamentals; absent it, these mentions are likely to fade. Falsifiers include material guidance revisions, deteriorating cash conversion, or BW failing to advance the project beyond limited authorization.

Key Decisions for Investors

• No trade on Cramer’s comments alone. For Rambus, wait for the Oct. 26 results and outlook; reconsider only if management identifies a measurable catalyst or the outlook materially disappoints. Avoid initiating a short solely on the broadcast remarks.
• Keep MiniMed on watch rather than buying against the single analyst target. Verify standalone financials and capital structure, then reassess whether operating performance supports the valuation; a target revision or weak guidance would invalidate the apparent upside anchor.
• Treat Babcock & Wilcox as high-risk optionality, not an earnings-backed project trade. Require confirmation of full notice to proceed, funding and execution terms before adding exposure; failure to progress the project is a thesis break.
• For ADM, consider an event-driven position only after checking processing margins, volumes and guidance expectations ahead of results. Do not use Deere as a direct hedge: its farm-equipment demand exposure is related to, but distinct from, ADM’s commodity-processing drivers.